Carboplatin childhood brain tumors Children Cancer Study Group Phase II trial October March Children Cancer Study Group institutions patients recurrent brain tumors Phase II trial carboplatin weeks Complete partial responses evaluable children brainstem glioma ependymoma medulloblastoma central nervous system primitive neuroectodermal tumor PNET none high-grade astrocytoma children medulloblastoma ependymoma central nervous system PNET prior cisplatin exposure responses prior cisplatin exposure responses Thirty-four percent patients absolute neutrophil count platelet count Sixteen percent moderate severe otoxicity nausea vomiting none nephrotoxicity 